
Capricor Therapeutics (CAPR) Stock Forecast & Price Target
Capricor Therapeutics (CAPR) Analyst Ratings
Bulls say
Capricor Therapeutics Inc. is advancing its clinical-stage biotechnology initiatives, particularly with deramiocel, a cell therapy currently in Phase 3 development for Duchenne muscular dystrophy (DMD). The favorable long-term benefit-risk profile of deramiocel, coupled with a partnership that enhances manufacturing capabilities and commercial preparation, positions the company for potential market entry in both the U.S. and Europe. The ongoing success of the HOPE-2 OLE study further supports optimism regarding the therapy's efficacy and safety, validating its transformative potential in addressing unmet medical needs in DMD treatment.
Bears say
Capricor Therapeutics is facing a negative outlook mainly due to the mixed clinical trial results for its product deramiocel, which showed a decline in the Performance of the Upper Limb 2.0 (PUL 2.0) score, indicating limited efficacy compared to the external comparator group. Additionally, the company's reliance on a series of successful clinical trials and the ability to secure necessary funding to advance its drug development is a significant concern, as any failures or inconclusive results could impede progress and investor confidence. Furthermore, the observed decline in disease progression over the trial years is marginal, raising doubts about the long-term viability of the therapies under development.
This aggregate rating is based on analysts' research of Capricor Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Capricor Therapeutics (CAPR) Analyst Forecast & Price Prediction
Start investing in Capricor Therapeutics (CAPR)
Order type
Buy in
Order amount
Est. shares
0 shares